Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3341-3356

  Weijer, Ruud ^a,b   Broekgaarden, Mans ^a   Krekorian, Massis ^a   Alles, Lindy K ^a   van Wijk, Albert C ^a   Mackaaij, Claire ^a   Verheij, Joanne ^a   van der Wal, Allard C ^a   van Gulik, Thomas M ^a   Storm, Gert ^b,c   Heger, Michal ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TWENTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cancer therapy; Drug delivery system; Extrahepatic cholangiocarcinoma; Hypoxia; Tumor targeting

Indexed keywords

ACRIFLAVINE; CD31 ANTIGEN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ENDOGLIN; GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; VASCULOTROPIN; HIF1A PROTEIN, HUMAN; MESSENGER RNA; RADIOSENSITIZING AGENT; TOPICAL ANTIINFECTIVE AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFICACY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BILE DUCT NEOPLASMS; CELL PROLIFERATION; CHEMISTRY; FLOW CYTOMETRY; GENETICS; HYPOXIA; KLATSKIN TUMOR; METABOLISM; PATHOLOGY; PHOTOCHEMOTHERAPY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ACRIFLAVINE; ANTI-INFECTIVE AGENTS, LOCAL; APOPTOSIS; BILE DUCT NEOPLASMS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA TOPOISOMERASES, TYPE I; FLOW CYTOMETRY; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KLATSKIN TUMOR; PHOTOCHEMOTHERAPY; RADIATION-SENSITIZING AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84962261901     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6490     Document Type: Article

References (74)

1. Garg AD, Nowis D, Golab J and Agostinis P. Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity. Apoptosis. 2010; 15:1050-1071.
2. Castano AP, Mroz P and Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nature Reviews Cancer. 2006; 6:535-545.
3. Szeimies RM, Morton CA, SidoroffA and Braathen LR. Photodynamic therapy for non-melanoma skin cancer. Acta Dermato-Venereologica. 2005; 85:483-490.
4. de Visscher SA, Dijkstra PU, Tan IB, Roodenburg JL and Witjes MJ. mTHPC mediated photodynamic therapy (PDT) of squamous cell carcinoma in the head and neck: a systematic review. Oral Oncology. 2013; 49:192-210.
5. Moghissi K and Dixon K. Update on the current indications, practice and results of photodynamic therapy (PDT) in early central lung cancer (ECLC). Photodiagnosis and Photodynamic Therapy. 2008; 5:10-18.
6. Qumseya BJ, David W and Wolfsen HC. Photodynamic therapy for Barrett's esophagus and esophageal carcinoma. Clinical Endoscopy. 2013; 46:30-37.
7. Wildeman MA, Nyst HJ, Karakullukcu B and Tan BI. Photodynamic therapy in the therapy for recurrent/persistent nasopharyngeal cancer. Head & Neck Oncology. 2009; 1:40.
8. Pinthus JH, Bogaards A, Weersink R, Wilson BC and Trachtenberg J. Photodynamic therapy for urological malignancies: past to current approaches. Journal of Urology. 2006; 175:1201-1207.
9. Lee TY, Cheon YK and Shim CS. Current status of photodynamic therapy for bile duct cancer. Clinical Endoscopy. 2013; 46:38-44.
10. Broekgaarden M, Weijer R, van Gulik TM, Hamblin MR and Heger M. Tumor cell survival pathways activated by photodynamic therapy: a molecular framework for inhibition strategies. Cancer and Metastasis Reviews, in press. 2015.
11. Casas A, Di Venosa G, Hasan T and Al B. Mechanisms of resistance to photodynamic therapy. Current Medicinal Chemistry. 2011; 18:2486-2515.
12. Gomer CJ. Induction of prosurvival molecules during treatment: rethinking therapy options for photodynamic therapy. Journal of the National Comprehensive Cancer Network. 2012; 10 Suppl 2:S35-39.
13. Kitagawa N, Kondo S, Wakisaka N, Zen Y, Nakanishi Y, Tsuji A, Endo K, Murono S and Yoshizaki T. Expression of seven-in-absentia homologue 1 and hypoxia-inducible factor 1 alpha: Novel prognostic factors of nasopharyngeal carcinoma. Cancer Letters. 2013; 331:52-57.
14. Theodoropoulos VE, Lazaris AC, Kastriotis I, Spiliadi C, Theodoropoulos GE, Tsoukala V, Patsouris E and Sofras F. Evaluation of hypoxia-inducible factor 1a overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma. BJU International. 2005; 95:425-431.
15. Weijer R, Broekgaarden M, Kos M, van Vught R, Rauws EAJ, Breukink E, van Gulik TM, Storm G and Heger M. Enhancing photodynamic therapy of refractory solid cancers: Combining second-generation photosensitizers with multi-targeted liposomal delivery. J Photochem Photobiol C: Photochem Rev. 2015; 23:103-131.
16. Ratcliffe PJ. Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. Journal of Physiology. 2013; 591:2027-2042.
17. Salceda S and Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitinproteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. Journal of Biological Chemistry. 1997; 272:22642-22647.
18. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, WykoffCC, Pugh CW, Maher ER and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399:271-275.
19. Chilov D, Camenisch G, Kvietikova I, Ziegler U, Gassmann M and Wenger RH. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1alpha. Journal of Cell Science. 1999; 112:1203-1212.
20. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ and Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 2011; 117:e207-217.
21. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer. 2008; 8:705-713.
22. Bracken CP, Whitelaw ML and Peet DJ. The hypoxiainducible factors: key transcriptional regulators of hypoxic responses. Cellular and Molecular Life Sciences. 2003; 60:1376-1393.
23. Semenza GL. Targeting HIF-1 for cancer therapy. Nature Reviews Cancer. 2003; 3:721-732.
24. Lu H, Dalgard CL, Mohyeldin A, McFate T, Tait AS and Verma A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. Journal of Biological Chemistry. 2005; 280:41928-41939.
25. Schofield CJ and Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nature Reviews Molecular Cell Biology. 2004; 5:343-354.
26. Rohwer N and Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resistance Updates. 2011; 14:191-201.
27. Meijer TW, Kaanders JH, Span PN and Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clinical Cancer Research. 2012; 18:5585-5594.
28. Mitra S, Cassar SE, Niles DJ, Puskas JA, Frelinger JG and Foster TH. Photodynamic therapy mediates the oxygenindependent activation of hypoxia-inducible factor 1alpha. Molecular Cancer Therapeutics. 2006; 5:3268-3274.
29. Krieg RC, Herr A, Raupach K, Ren Q, Schwamborn K and Knuechel R. Analyzing effects of photodynamic therapy with 5-aminolevulinic acid (ALA) induced protoporphyrin IX (PPIX) in urothelial cells using reverse phase protein arrays. Photochemical & Photobiological Sciences. 2007; 6:1296-1305.
30. Ferrario A and Gomer CJ. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model. Journal of Environmental Pathology, Toxicology and Oncology. 2006; 25:251-259.
31. Ferrario A and Gomer CJ. Targeting the 90 kDa heat shock protein improves photodynamic therapy. Cancer Letters. 2010; 289:188-194.
32. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS and Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Research. 2000; 60:4066-4069.
33. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A and Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemotherapy and Pharmacology. 2005; 56:569-577.
34. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W and Meyer zum Buschenfelde KH. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. Journal of Hepatology. 1985; 1:579-596.
35. Broekgaarden M, Kos M, Jurg FA, van Beek AA, van Gulik TM and Heger M. Inhibition of NF-kappaB in tumor cells exacerbates immune cell activation following photodynamic therapy. International Journal of Molecular Sciences. 2015; 16:19960-19977.
36. Broekgaarden M, de Kroon AI, Gulik TM and Heger M. Development and in vitro proof-of-concept of interstitially targeted zinc-phthalocyanine liposomes for photodynamic therapy. Current Medicinal Chemistry. 2014; 21:377-391.
37. Lee K, Zhang H, Qian DZ, Rey S, Liu JO and Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:17910-17915.
38. Wainwright M. Acridine-a neglected antibacterial chromophore. Journal of Antimicrobial Chemotherapy. 2001; 47:1-13.
39. Yin T, He S, Shen G and Wang Y. HIF-1 dimerization inhibitor acriflavine enhances antitumor activity of sunitinib in breast cancer model. Oncology Research. 2015; 22:139-145.
40. Wong CC-L, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME and Semenza GL. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastastic niche formation and lung metastasis. Journal of Molecular Medicine. 2012; 90:803-815.
41. Hassan S, Laryea D, Mahteme H, Felth J, Fryknas M, Fayad W, Linder S, Rickardson L, Gullbo J, Graf W, Pahlman L, Glimelius B, Larsson R and Nygren P. Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Science. 2011; 102:2206-2213.
42. Dwarakanath BS, Khaitan D and Mathur R. Inhibitors of topoisomerases as anticancer drugs: problems and prospects. Indian Journal of Experimental Biology. 2004; 42:649-659.
43. Berra E, Roux D, Richard DE and Pouysségur J. Hypoxiainducible factor-1a (HIF-1a) escapes O2-driven proteasomal degradation irrespective of its subcellular localization: nucleus or cytoplasm. EMBO Reports. 2001; 2:615-620.
44. Thurston G, McLean JW, Rizen M, Baluk P, Haskell A, Murphy TJ, Hanahan D and McDonald DM. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. Journal of Clinical Investigation. 1998; 101:1401-1413.
45. Krammer B. Vascular effects of photodynamic therapy. Anticancer Research. 2001; 21:4271-4277.
46. Chen B, Pogue BW, Hoopes PJ and Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. International Journal of Radiation Oncology, Biology, and Physics. 2005; 61:1216-1226.
47. Wang GL, Jiang BH, Rue EA and Semenza GL. Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92:5510-5514.
48. Semenza GL, Roth PH, Fang H-M and Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. Journal of Biological Chemistry. 1994; 269:23757-23763.
49. Papandreou I, Cairns RA, Fontana L, Lim AL and Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metabolism. 2006; 3:187-197.
50. Vos SM, Tretter EM, Schmidt BH and Berger JM. All tangled up: how cells direct, manage and exploit topoisomerase function. Nature Reviews Molecular Cell Biology. 2011; 12:827-841.
51. Ruys AT, van Haelst S, Busch OR, Rauws EA, Gouma DJ and van Gulik TM. Long-term survival in hilar cholangiocarcinoma also possible in unresectable patients. World Journal of Surgery. 2012; 36:2179-2186.
52. Weijer R, Broekgaarden M, van Golen RF, Bulle E, Nieuwenhuis E, Jongejan A, Moerland PD, van Kampen AHC, van Gulik TM and Heger M. Low-power photodynamic therapy induces survival signaling in perihilar cholangiocarcinoma cells. Manuscript in preparation. 2015.
53. Chen W-H, Lecaros RLG, Tseng Y-C, Huang L and Hsu Y-C. Nanoparticle delivery of HIF1a siRNA combined with photodynamic therapy as a potential treatment strategy for head-and-neck cancer. Cancer Letters. 2015; 359:65-74.
54. Bhuvaneswari R, Yuen GY, Chee SK and Olivo M. Hypericin-mediated photodynamic therapy in combination with Avastin (bevacizumab) improves tumor response by downregulating angiogenic proteins. Photochemical & Photobiological Sciences. 2007; 6:1275-1283.
55. Solban N, Selbo PK, Sinha AK, Chang SK and Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Research. 2006; 66:5633-5640.
56. Strese S, Fryknas M, Larsson R and Gullbo J. Effects of hypoxia on human cancer cell line chemosensitivity. BMC Cancer. 2013; 13:331.
57. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH and Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications. Cancer Research. 2004; 64:1475-1482.
58. Beretta GL, Perego P and Zunino F. Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors. Expert Opinion on Therapeutic Targets. 2008; 12:1243-1256.
59. McDonald A and Brown R. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors. British Journal of Cancer. 1998; 78:745.
60. Moon Y, Dahlberg W, Yu Y, Ohno T, Todoroki T and Little J. Radiosensitivity of human biliary tract cancer cell lines in vitro. International Journal of Oncology. 1997; 10:545-551.
61. Shetty S, Shetty P, Idell S, Velusamy T, Bhandary YP and Shetty RS. Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53. Journal of Biological Chemistry. 2008; 283:19570-19580.
62. Gramling MW and Church FC. Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment. Thrombosis Research. 2010; 125:377-381.
63. Kwaan HC, Mazar AP and McMahon BJ. The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Seminars in Thrombosis and Hemostasis. 2013; 39:382-391.
64. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Nöel A and Foidart J-M. The pro-or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB Journal. 2002; 16:147-154.
65. Heger M. Editor's inaugural issue foreword: perspectives on translational and clinical research. Journal of Clinical and Translational Research. 2015; 1:1-5.
66. Rouser G, Fkeischer S and Yamamoto A. Two dimensional then layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots. Lipids. 1970; 5:494-496.
67. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, Idu MM, van Maldegem F, Aten J and van der Wal AC. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. Journal of Pathology. 2010; 220:499-508.
68. van der Loos CM. Chromogens in multiple immunohistochemical staining used for visual assessment and spectral imaging: the colorful future. Journal of Histotechnology. 2010; 33:31-40.
69. Broekgaarden M, Weijer R, van Wijk AC, Cox RC, Egmond MR, Hoebe R, Van Gulik TM and Heger M. Photodynamic therapy with liposomal zinc phtalocyanine and tirapazamine increases tumor cell death via DNA damage. Manuscript in preparation. 2015.
70. Laemmli sample buffer (2X). Cold Spring Harbor Protocols. 2006; 2006:pdb.rec10424.
71. Ji Z, Yang G, Shahzidi S, Tkacz-Stachowska K, Suo Z, Nesland JM and Peng Q. Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Letters. 2006; 244:182-189.
72. Ruijter JM, Ramakers C, Hoogaars WM, Karlen Y, Bakker O, van den HoffMJ and Moorman AF. Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Research. 2009; 37:e45.
73. Vichai V and Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols. 2006; 1:1112-1116.
74. Schneider CA, Rasband WS and Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nature Methods. 2012; 9:671-675.